Healthtech SMEs looking to upscale their US concern person a constricted clip near to use to the 2023 ABHI US Accelerator, developed by the Association of British HealthTech Industries (ABHI).
Now successful its 5th year, the ABHI US Accelerator is aimed astatine UK aesculapian device, diagnostic and integer wellness companies looking to pat into opportunities to grow their scope cross-Atlantic. The 12-month programme of enactment provides them with the accidental to specify and fortify their US strategy, de-risk marketplace introduction and turn their US concern by utilising ABHI’s advice, expertise, and connections wrong the country.
The yearly programme, conducted successful concern with the Dell Medical School successful Austin, Texas provides entree to ABHI’s US network, including in-market specialists to usher companies connected circumstantial issues, including regulation, reimbursement, and exertion appraisal. The programme besides facilitates introductions to hospital, objective champions, and proviso concatenation leaders, enabling companies to liaise straight with decision-makers to sermon their products and services.
Successful applicants volition person week-long commercialized missions crossed the US, providing them with opportunities to prosecute with stakeholders for their idiosyncratic institution objectives and contiguous proven UK healthtech to caller clients.
With 60% of places already filled, companies keen to instrumentality vantage of the connection person until the 31st October to use for the ABHI’s 2023 cohort.
Paul Benton, managing director, international, ABHI said: “We are excited to person expanded our 2023 programme to enactment adjacent much companies turn their US concern by taking vantage of the beardown web of hospital, objective and proviso concatenation leaders we person built crossed the country. Wrapped astir this connection is simply a dedicated ngo programme to cardinal US states, with an exceptional acceptable of mentors connected manus to support. It is often described by companies wrong the programme arsenic being their astir cost-effective selling walk ever.”
As portion of the programme, ABHI secretariat enactment hand-in-hand with each company, mounting milestones and goals that enactment institution growth. They enactment aboriginal stage, pre-FDA approved companies, helping them to navigate the FDA process, make marketplace research, and acceptable up proceedings sites, each the mode up to much established SME’s with pre-existing income successful the US.
Richard Jones, president and main strategy serviceman astatine C2-Ai, a subordinate of the 2022 cohort, said: “In elemental terms, the ABHI Accelerator has been the astir cost-effective selling walk ever. Our attack to reducing outgo and harm crossed hospitals is unsocial and gaining immense traction globally. However, the ABHI opens doors to person discussions with elder leaders with the starring hospitals successful the regions they visit. That gives america a level to prosecute with radical that mightiness different beryllium hard to access. It's a implicit no-brainer to motion up for adjacent year.”
Nick de Pennington, laminitis & CEO, Ufonia who person rejoined the programme for a 2nd year, added: “It has been rather astonishing to person this level of entree and engagement from the elder enactment teams of immoderate of the largest healthcare organisations wrong the US. The ABHI US Accelerator accidental has been invaluable for our company, allowing america to marque connections and recognize the needs of extremity users and determination makers, truthful that we tin efficaciously deploy and scale-up our concern successful the US market.”
English (US)